BioSight
Companies
LB PHARMACEUTICALS INC logo

LBRX

NASDAQNEW YORK, NY
LB PHARMACEUTICALS INC

LB Pharmaceuticals is developing LB-102, a drug candidate in clinical development for treating patient populations where the company believes its approach can predict treatment outcomes. LB-102 is being evaluated across multiple indications, with the company also exploring additional therapeutic applications for the candidate. LB Pharmaceuticals relies on third-party manufacturers and collaborators to advance its clinical programs and is seeking funding to complete development and potential commercialization of LB-102.

Price history not yet available for LBRX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar